Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer.

Summary: Lung cancer is notoriously difficult to treat because tumors often figure out how to resist the drugs meant to destroy them. To solve this, scientists developed a new way to grow tiny, 3D models of a patient's exact tumor using fluid collected from their lungs. These tiny models, called organoids, are incredibly accurate—they matched how real patients responded to treatments almost 90% of the time! By studying these organoids, researchers figured out exactly how some lung cancers resist a common targeted drug. Even better, they discovered that a common everyday medicine, ibuprofen, might help the cancer drug work again. This exciting new tool could help doctors pick the perfect, personalized medicine for each lung cancer patient.